Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price objective lifted by Piper Jaffray Companies from $20.00 to $26.00 in a research note issued to investors on Thursday morning. They currently have an overweight rating on the biopharmaceutical company’s stock.
A number of other brokerages have also commented on HALO. BidaskClub raised shares of Halozyme Therapeutics from a buy rating to a strong-buy rating in a research report on Saturday, June 24th. Barclays PLC reaffirmed an overweight rating and set a $16.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. Canaccord Genuity set a $16.00 price objective on shares of Halozyme Therapeutics and gave the company a buy rating in a research report on Wednesday, July 26th. Jefferies Group LLC reaffirmed an underperform rating and set a $7.00 price objective (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Finally, Zacks Investment Research lowered shares of Halozyme Therapeutics from a buy rating to a hold rating in a research report on Thursday, August 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. Halozyme Therapeutics currently has a consensus rating of Hold and an average target price of $16.00.
Shares of Halozyme Therapeutics (HALO) traded up 1.69% during mid-day trading on Thursday, hitting $16.25. The stock had a trading volume of 5,824,402 shares. The company’s market cap is $2.18 billion. Halozyme Therapeutics has a one year low of $8.18 and a one year high of $16.65. The firm’s 50 day moving average price is $12.79 and its 200-day moving average price is $13.23.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.76 million. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.21) EPS. On average, equities research analysts anticipate that Halozyme Therapeutics will post ($0.88) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new position in Halozyme Therapeutics in the second quarter worth about $171,000. Verition Fund Management LLC raised its position in Halozyme Therapeutics by 50.4% in the second quarter. Verition Fund Management LLC now owns 20,499 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 6,866 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Halozyme Therapeutics by 524.7% in the second quarter. The Manufacturers Life Insurance Company now owns 1,011,449 shares of the biopharmaceutical company’s stock worth $12,968,000 after purchasing an additional 849,545 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Halozyme Therapeutics in the second quarter worth about $131,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Halozyme Therapeutics in the second quarter worth about $541,000. 85.08% of the stock is owned by hedge funds and other institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.